Inhibition of IL-17A in Tumor Microenvironment Augments Cytotoxicity of Tumor-Infiltrating Lymphocytes in Tumor-Bearing Mice
Figure 1
Inhibition of IL-17A at tumor sites suppresses tumor growth.
(A, left panel) 1×106 B16 tumor cells were injected subcutaneously into C57BL/6 mice, and PBS, Ad-SNC, or Ad-si-IL-17 with 1×109 PFU was injected intratumorally at 7, 10, and 13 d. Data represent means ± SE (n = 7 mice per group of two independent experiments). *P<0.05, one-way ANOVA. (A, right panel) 5×105 MC38 tumor cells were injected subcutaneously into mice, in the same way adenovirus vectors were injected at 5, 8, and 11 d. Data represent means ± SE (n = 7 mice of two independent experiments). *P<0.05, one-way ANOVA. (B).Levels of IL-17A protein were measured by ELISA in tumor lysates from mice after having been treated with PBS, Ad-SNC, or Ad-si-IL-17. In B16 and MC38 tumor tissues, Ad-si-IL-17 treatment showed lower levels of IL-17A compared with PBS or Ad-SNC treatment. Data are representative of two independent experiments. Data are presented as means ± SE (n = 4). *P<0.05, Student's t test.